NGM Biopharmaceuticals is a technology company.
NGM Biopharmaceuticals has raised $260.0M across 4 funding rounds.
NGM Biopharmaceuticals has raised $260.0M in total across 4 funding rounds.
NGM Biopharmaceuticals has raised $260.0M in total across 4 funding rounds.
NGM Biopharmaceuticals's investors include ARCH Venture Partners, Atlas Venture, Foresite Capital, The Column Group.
NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company discovering and developing novel therapeutics targeting key biological pathways in liver and metabolic diseases, retinal diseases, oncology, cardio-metabolic conditions, and ophthalmic disorders.[1][2][3] It serves patients with unmet medical needs by leveraging a biology-centric drug discovery approach to advance proprietary drug candidates, several in clinical development, including NGM120—a GDF15/GFRAL antagonist antibody in Phase 2 trials for hyperemesis gravidarum (extreme pregnancy sickness) and cancer cachexia.[2][5] The company demonstrates growth momentum through an expanding pipeline and recent initiation of the EMERALD Phase 2 trial for NGM120, positioning it to address large unmet needs in transformative medicines.[2][5]
Founded in 2007 and headquartered in South San Francisco, California, NGM Biopharmaceuticals emerged as a biotech innovator focused on biology-driven drug discovery.[1] Key leaders include CEO David J. Woodhouse, Ph.D., CSO Dan Kaplan, Ph.D., CMO Hsiao D. Lieu, M.D., President & CFO Siobhan Nolan Mangini, and General Counsel Valerie Pierce, guiding its evolution from early research into a NASDAQ-listed entity (ticker: NGM).[1] Pivotal moments include building a robust pipeline with proof-of-concept studies and clinical advancements, such as the ongoing EMERALD trial, reflecting steady traction in harnessing novel biological insights.[2][5]
NGM rides the wave of precision medicine and biologics innovation, targeting overactivated pathways like GDF15/GFRAL in metabolic and cachexia-related disorders amid rising demand for targeted therapies in oncology, liver disease, and women's health.[2][5] Timing aligns with advances in antibody therapeutics and growing recognition of conditions like hyperemesis gravidarum, fueled by market forces such as aging populations, obesity epidemics, and post-pandemic focus on metabolic health.[1][3] As a NASDAQ-listed player, NGM influences the biotech ecosystem by contributing to pipeline diversity and validating novel targets, potentially accelerating industry-wide adoption of biology-driven platforms.[2]
NGM is poised for milestone readouts from the EMERALD Phase 2 trial of NGM120, which could validate its platform in hyperemesis gravidarum and expand into cancer cachexia, unlocking blockbuster potential in underserved areas.[5] Trends like AI-enhanced discovery, combination therapies, and regulatory emphasis on rare diseases will shape its trajectory, with pipeline growth likely amplifying its influence as a nimble biotech innovator.[2] Returning to its biology-driven roots, NGM's momentum positions it to deliver transformative impact for patients facing disease-disrupted lives.[4][5]
NGM Biopharmaceuticals has raised $260.0M across 4 funding rounds. Most recently, it raised $120.0M Series A in July 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2024 | $120.0M Series A | ARCH Venture Partners, Atlas Venture, Foresite Capital, The Column Group | |
| Mar 1, 2015 | $58.0M Series D | ARCH Venture Partners, Atlas Venture, Foresite Capital, The Column Group | |
| Mar 1, 2010 | $55.0M Series B | ARCH Venture Partners, Atlas Venture, Foresite Capital, The Column Group | |
| Dec 1, 2009 | $27.0M Series A | ARCH Venture Partners, Atlas Venture, Foresite Capital, The Column Group |